Correction: Therapeutic Administration of the Chemokine CXCL1/KC Abrogates Autoimmune Inflammatory Heart Disease
Main Author: | The Staff |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065052/?tool=EBI |
Similar Items
-
Correction: Therapeutic Administration of the Chemokine CXCL1/KC Abrogates Autoimmune Inflammatory Heart Disease.
Published: (2014-01-01) -
Therapeutic administration of the chemokine CXCL1/KC abrogates autoimmune inflammatory heart disease.
by: Kurt Bachmaier, et al.
Published: (2014-01-01) -
Characterization of thymic hyperplasia associated with autoimmune Myasthenia Gravis : role of the chemokines CXCL12 and CXCL13
by: Weiss, Julia
Published: (2011) -
Characterization of thymic hyperplasia associated with autoimmune Myasthenia Gravis : role of the chemokines CXCL12 and CXCL13
by: Weiss, Julia Miriam
Published: (2011) -
Intranasal administration of recombinant TRAIL down-regulates CXCL-1/KC in an ovalbumin-induced airway inflammation murine model.
by: Veronica Tisato, et al.
Published: (2014-01-01)